^
    Back
    Association details:
    Biomarker:NRAS mutation + U2AF1 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Blood Adv
    Title:

    Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

    Published date:
    04/22/2021
    Excerpt:
    ...patients treated with HMA+VEN–based regimens at The University of Texas MD Anderson Cancer Center...RAS mutations were enriched in patients with U2AF1 mutations and associated with inferior outcomes (median OS, 8 months)...active signaling mutations...K/NRAS)...RAS mutations were enriched in patients with U2AF1 mutations and associated with numerically lower CRc (and MRD− CR) rates.
    Secondary therapy:
    Hypomethylating agent
    DOI:
    https://doi.org/10.1182/bloodadvances.2020004173